BioDrone Therapeutics Inc.
  • Home
  • About Us
  • Our Sciences
    • Cell-Derived Vesicle
    • BioDrone™ Platform
    • Manufacturing
    • Intellectual Properties
  • Pipeline
  • Publications
    • Publications
    • Posters & Presentations
  • Business
    • Business Model
    • Open Innovation
  • News
    • Press Releases
  • More
    • Home
    • About Us
    • Our Sciences
      • Cell-Derived Vesicle
      • BioDrone™ Platform
      • Manufacturing
      • Intellectual Properties
    • Pipeline
    • Publications
      • Publications
      • Posters & Presentations
    • Business
      • Business Model
      • Open Innovation
    • News
      • Press Releases
BioDrone Therapeutics Inc.
  • Home
  • About Us
  • Our Sciences
    • Cell-Derived Vesicle
    • BioDrone™ Platform
    • Manufacturing
    • Intellectual Properties
  • Pipeline
  • Publications
    • Publications
    • Posters & Presentations
  • Business
    • Business Model
    • Open Innovation
  • News
    • Press Releases

BUSINESS MODEL

Next-Generation Cell Therapy or Drug Delivery Collaboration

MDimune is currently seeking partners for R&D collaborations that utilize the BioDrone™(CDVs) platform for next-generation cell therapies or targeted payload delivery.

R&D collaboration involves the development of CDVs tailored to customers' need (MDimune) and rigorous testing in a relevant model system (Partner). The current focus is on (1) the development of the next-generation cell therapy candidates and (2) novel bio-safe DDS (drug delivery system) enabled to deliver payloads of interest including siRNA, ASOs, mRNA and others, 


The standard agreement includes the following: 


  • Upfront Payment, Development, Regulatory and Sales Milestones, and Royalties
  • Other deal structures, including co-development or option-based transactions, will be considered
  • R&D Funding to cover all expenses incurred by MDimune

Copyright © 2022 BioDrone Therapeutics Inc. - All Rights Reserved.

  • Contact